Beijing Strong Biotechnologies,Inc. (BEIJING STRONG BIOTECHNOLOGIES ) Aktie

Beijing Strong Biotechnologies,Inc. researches, develops, manufactures, and sells in-vitro diagnostics (IVD) products and services in China and internationally. The company offers biochemistry reagents, including liver, renal, lipid, cardiac, diabetes, special protein, tumor marker, pancreas, inorganic, inflammation, TDM, and other panels; and coagulation products, such as prothrombin time, activated partial thromboplastin time, thrombin time, and fibrinogen, as well as antithrombin III, von Willebrand factor antigen, protein S activity, protein C, lupus anticoagulant, fibrin degradation products, and d-dimer. It also provides blood grouping card comprising ABO blood type anti stereotype detection card, DiaClon ABD-confirmation, and DiaClon ABO/D+ reverse grouping for patients; and automatic coagulation analyzer, automatic biochemistry analyzer, fully automatic chemiluminescence immunoassay analyzer, and automated blood groupings analyzer. In addition, the company provides technology and document services. It sells its products under the GCELL and Beijing MDC brands. The company was founded in 2001 and is based in Beijing, China.